GCN2 Has Inhibitory Effect on Human Immunodeficiency Virus-1 Protein Synthesis and Is Cleaved upon Viral Infection by Pino, Javier del et al.
GCN2 Has Inhibitory Effect on Human Immunodeficiency
Virus-1 Protein Synthesis and Is Cleaved upon Viral
Infection
Javier del Pino1, Jose´ Luis Jime´nez2, Iva´n Ventoso1, Alfredo Castello´1¤, Ma A´ngeles Mun˜oz-Ferna´ndez3,
Ce´sar de Haro1, Juan Jose´ Berlanga1*
1Centro de Biologı´a Molecular Severo Ochoa (CSIC-UAM), Universidad Auto´noma de Madrid, Madrid, Spain, 2 Plataforma de Laboratorio, Hospital General Universitario
Gregorio Maran˜o´n, Madrid, Spain, 3 Laboratory of Molecular Immunobiology, Hospital General Universitario Gregorio Maran˜o´n, Madrid, Spain
Abstract
The reversible phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 (eIF2alpha) is a well-
characterized mechanism of translational control in response to a wide variety of cellular stresses, including viral infection.
Beside PKR, the eIF2alpha kinase GCN2 participates in the cellular response against viral infection by RNA viruses with
central nervous system tropism. PKR has also been involved in the antiviral response against HIV-1, although this antiviral
effect is very limited due to the distinct mechanisms evolved by the virus to counteract PKR action. Here we report that
infection of human cells with HIV-1 conveys the proteolytic cleavage of GCN2 and that purified HIV-1 and HIV-2 proteases
produce direct proteolysis of GCN2 in vitro, abrogating the activation of GCN2 by HIV-1 RNA. Transfection of distinct cell
lines with a plasmid encoding an HIV-1 cDNA clone competent for a single round of replication resulted in the activation of
GCN2 and the subsequent eIF2alpha phosphorylation. Moreover, transfection of GCN2 knockout cells or cells with low levels
of phosphorylated eIF2alpha with the same HIV-1 cDNA clone resulted in a marked increase of HIV-1 protein synthesis. Also,
the over-expression of GCN2 in cells led to a diminished viral protein synthesis. These findings suggest that viral RNA
produced during HIV-1 infection activates GCN2 leading to inhibition of viral RNA translation, and that HIV-1 protease
cleaves GCN2 to overcome its antiviral effect.
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Introduction
The control of protein synthesis is central to the global process
of regulation of gene expression, first leading to translational
reprogramming and, as a consequence, affecting the transcrip-
tional profile of cells. Protein synthesis is basically regulated at the
initiation step, where phosphorylation of the alpha subunit of
initiation factor eIF2 (eIF2alpha) at residue Ser-51 by specific
protein kinases represents one of the best-characterized mecha-
nisms regulating mRNA translation in eukaryotic cells in response
to various stress conditions, such as lack of nutrients, endoplasmic
reticulum stress, iron deficiency, heat shock and viral infection
[1,2]. In mammalian cells, four different eIF2alpha kinases
regulated by specific signals have been identified: HRI (iron
deficiency) [3,4]; PKR (double-stranded RNA produced in cells
infected by viruses) [5]; PERK (stress situations in the endoplasmic
reticulum) [1]; and GCN2 (amino acid or serum deprivation and
ultraviolet light irradiation) [6,7,8]. Some members of this family
of eIF2alpha kinases are also present in other eukaryotic
organisms: PERK and GCN2 in Drosophila melanogaster [5,9,10];
GCN2 in the yeast Saccharomyces cerevisiae [11] and two eIF2alpha
kinases related to mammalian HRI (Hri1 and Hri2), in addition to
Gcn2, in the fission yeast Schizosaccharomyces pombe [12].
eIF2 forms a ternary complex with GTP and the initiator
methionyl-tRNA, which delivers the latter to the small ribosomal
subunit with the subsequent hydrolisis of GTP. The conversion of
inactive eIF2-GDP into active eIF2-GTP is catalyzed by the
guanine nucleotide exchange factor eIF2B. Phosphorylation of
eIF2alpha at Ser-51 increases its affinity for eIF2B, which then
becomes sequestered in a stable and inactive complex, leading to
the inhibition of protein synthesis due to the lack of ternary
complexes.
GCN2 was first described in the budding yeast Saccharomyces
cerevisiae where the kinase is activated in response to amino acid
starvation through the binding of uncharged tRNA to a region
homologous to the histidyl-tRNA synthetases (HisRS) [13]. In
mammals, this region is also responsible for the in vitro activation
of GCN2 by tRNA and viral RNA [14]. Thus GCN2 has been
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involved in the antiviral response against RNA viruses, such as
Semliki Forest virus, vesicular stomatitis virus and Sindbis virus
(SV), whose genomic RNA is able to bind and activate the kinase,
which through the phosphorylation of eIF2alpha inhibits the
translation of the genomic mRNA of SV and blocks its replication
cycle in cells [14]. It is well known the central role of PKR in the
cellular antiviral response as well as the different strategies
developed by distinct viruses in order to counteract the negative
effects of PKR on virus replication. These evasion strategies
include proteins that inhibit PKR, sequester dsRNA, or are
pseudosubstrates, and RNA molecules acting as pseudoactivators
that compete with activator dsRNA for the binding to PKR [15].
Thus, during HIV-1 infection, PKR is first transiently activated
and then inhibited due to viral and virus-activated cellular
mechanisms of control [16,17].
Many viruses have evolved mechanisms that modify the activity
of cellular translation factors in order to favor viral mRNA
translation to the detriment of cellular mRNA translation. The
best-characterized example of that is the proteolityc cleavage of
eIF4G by proteases of different viruses, leading to the inhibition of
capped cellular mRNA translation and to the enhancement of
translation of uncapped viral RNAs [18]. Thus, eIF4G is cleaved
by 2A protease of rhinovirus or poliovirus, L protease of
aphthovirus, and proteases of several retroviruses, including
HIV-1 and HIV-2 [19,20,21]. Another protein involved in
translation, PABP, is also a target for viral proteases, including
2A and 3C of enterovirus [22,23], and the proteases of HIV-1 and
HIV-2 [24].
HIV-1 protein translation occurs late in the viral life cycle in the
cytoplasm of cells and is carried out by the host protein synthesis
machinery. HIV-1 protease (HIV-1Pro) is a small enzyme that
mediates the cleavage of Gag, Gag-Pol, and Nef precursor
polyproteins during virion assembly and maturation [16].
In this paper we show that HIV-1 RNA activates GCN2 in vivo
and in vitro and that the cleavage of the kinase by HIV-1Pro leads
to its inactivation. Synthesis of HIV-1 proteins in cells transfected
with a plasmid encoding the viral RNA increased in cells devoid of
the GCN2 gene. All these results suggest that GCN2 is involved in
the cellular antiviral response against HIV-1 infection.
Results
HIV-1 RNA promotes GCN2 activation in vitro through its
HisRS-related domain
Given that the genomic RNA of Sindbis virus activated GCN2
in vitro and that GCN2 have an antiviral effect against this virus
[14], we tested whether the genomic RNA of other viruses could
activate GCN2 as a sign of a potential antiviral effect against them.
We observed that in vitro transcribed HIV-1 genomic RNA,
among others, was able to significantly increase the eIF2alpha
kinase activity of affinity purified GCN2 in a dose-dependent
manner (Figure 1A). This activation was dependent on its HisRS-
related domain, as the GCN2-m2 mutant of this domain showed
very low autophosphorylation and eIF2alpha kinase activity
compared to that of the wild type protein (Figure 1B). As
expected, no autophosphorylation or eIF2alpha kinase activity was
found when using the GCN2 form bearing a mutation in the lysine
residue of the kinase domain responsible for the ATP binding
(K618R). GCN2 activation by HIV-1 RNA was comparable to
that obtained by using Sindbis virus RNA, which served as a
positive control in these assays.
GCN2 cleavage in cells after HIV-1 infection
In order to investigate the putative role of GCN2 in the cellular
antiviral response against HIV-1, we tested GCN2 activation in
MT-2 (human T-lymphocyte cell line) cells infected with HIV-1.
To our surprise, the analysis of the cell lysates revealed the
disappearance of GCN2 upon HIV-1 infection coinciding with the
cleavage and disappearance of full length eIF4GI. Both protein
bands were apparently intact at day 1, but disappeared at day 3
after infection, and their cleavage was prevented in presence of the
specific inhibitor of the HIV-1 protease (HIV-1Pro) saquinavir
(Figure 1 C and D). In the case of GCN2 we were unable to detect
any proteolytic fragment, but the cleavage of eIF4GI rendered the
expected carboxi-terminal Ct-2 (about 102 kDa) and Ct-3 (about
57 kDa) fragments [20]. Moreover, infection of Peripheral Blood
Mononuclear Cells (PBMC) with HIV-1 resulted in a significant
proteolytic degradation of GCN2 (45% reduction) and eIF4GI at 4
and 5 dpi, which was prevented in the presence of saquinavir
(Figure 1E), strongly suggesting that the low levels of these proteins
present in the cells were a consequence of HIV-1Pro cleavage. The
level of other proteins such as PKR, actin or eIF2alpha remained
unaltered to the same extent throughout the experiment. Note that
in Figure 1 D and E, the HIV-1 p24 protein only appeared in the
absence of saquinavir as a consequence of HIV-1Pro processing of
the Gag (55 kDa) precursor. We also observed increased
phosphorylation of eIF2alpha upon HIV-1 infection (Figure 1 C
and E), suggesting a possible activation of GCN2.
HIV-1 protease directly cleaves GCN2
Next, we tested the ability of HIV-1Pro to cleave GCN2 by using
different approaches. First, we checked the cleavage of GCN2 in
cells where the protease was expressed in a context in which other
HIV-1 proteins were absent. With this aim, we expressed HIV-
1Pro in BHK-21 cells by electroporation of an in vitro transcribed
RNA bearing the protease-coding region in the context of SV
genomic mRNA [25]. As controls we used similar RNAs in order
to express the 2A protease of poliovirus (PV-2APro) or just SV
capsid C protein (Figure 2A). At 4 hours post-electroporation, we
could observe a marked decrease in the amount of endogenous
GCN2 and the appearance of a proteolytic fragment of an
apparent molecular weight of 130–140 kDa, accounting for a
specific cleavage of GCN2 by HIV-1Pro. In contrast, PV-2APro was
unable to cut GCN2, but, as expected, eIF4GI was proteolytically
degraded by both PV-2APro and HIV-1Pro. We also assayed the
proteolytic activity of HIV-1Pro on GCN2 in COS-7 cells
transfected with pTM1-derived plasmids and infected with
vaccinia virus encoding T7 polymerase (Figure 2B). Co-expression
of HIV-1Pro with mouse or human GCN2 resulted in the
production of a cleavage fragment similar to the one obtained in
BHK-21 cells expressing the protease.
To further study GCN2 proteolytic degradation we performed
experiments in which purified HIV-1Pro was added to HeLa cell-
free extracts. Complete proteolysis of GCN2 was achieved after
only 15 min of incubation, whereas in the same extracts a
significant amount of eIF4GI remained intact after 30 min
(Figure 2D). The cleavage of both proteins was prevented when
the protease was used in the presence of saquinavir. PABP,
another known HIV-1Pro substrate, seemed to be processed to a
much lower extent and the amount of other proteins such as actin
did not experience significant changes.
Moreover, affinity-purifed mouse and human GCN2 were
cleaved in vitro after incubation with purified HIV-1Pro and HIV-
2Pro (Figure 2C). Both viral proteases rendered GCN2 proteolytic
fragments of the same size, suggesting that these proteases directly
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cleaved both mouse and human GCN2 at the same, or a very
close, site.
Identification of the HIV-1 protease cleavage site on
GCN2
Given that HIV-1Pro produced a direct proteolytic break in
GCN2, we next tried to identify the precise site/s of cleavage.
Based on the size of the major GCN2 fragment obtained by the
action of the protease, we constructed bacterial expression
plasmids in order to express and purify GST fusion proteins
bearing a portion of mouse (aa 419–1024) or human (aa 525–
1024) GCN2, which was supposed to contain the cleavage site. We
used truncated recombinant proteins due to the low yield of full-
length GCN2 protein in bacteria. Protease treatment produced a
major carboxy-terminal fragment with an apparent molecular
weight of about 67 kDa in both mouse and human proteins
(Figure 2E). In the case of the human protein there was a minor
additional product of about 73 kDa which could account for a
secondary cleavage site. The major 67 kDa polypeptide was
subjected to amino-terminal sequencing by using the Edman
degradation method, which rendered the amino acid sequences
VETVIP for the human protein and IETVIP for the mouse
protein, which correspond to a cleavage site between residues 560
and 561 or 559 and 560, respectively. Thus the cleavage sites
identified are compatible with the size of the carboxi-terminal
Figure 1. HIV-1 RNA activates GCN2 and the kinase is proteolytically cleaved during HIV-1 infection. (A) Purified mouse GCN2 was
subjected to in vitro eIF2alpha kinase assay in the presence of increasing concentrations of in vitro transcribed RNAs corresponding to the mouse
GCN2 open reading frame (as a negative control), or to the genomic RNAs of Sindbis virus or HIV-1, respectively, as indicated. In this experiment 32P-
c-ATP was included in the kinase reaction mix and phosphorylation of eIF2alpha was visualized after analysis by SDS-PAGE and autoradiography. (B)
In vitro eIF2alpha kinase assay of purified wild type GCN2 (WT), GCN2-K618R (K618R) or GCN2-m2 (m2) in the presence of Sindbis virus (SV) or HIV-1
RNA, as indicated. Results were obtained by western blot analysis of the samples using different antisera to detect eIF2alpha phosphorylated on
serine 51, total eIF2alpha and phosphorylated and total GCN2. (C) MT-2 cells were mock infected (2) or infected with 10 or 100 ng of p24gag per 106
cells of HIV-1NL4–3 and harvested at the indicated days post-infection (D.P.I.). Aliquots of cell lysates containing equal amount of proteins were
analyzed by western blot (8% SDS-PAGE) using specific antibodies as indicated. (D) MT-2 cells were mock-infected (2) or infected with 100 ng of HIV-
1 NL4-3 per 106 cells, in the absence or the presence of the indicated concentrations of saquinavir (SQ) and harvested at day 3 post-infection. Aliquots
of cell lysates containing equal amounts of proteins were analyzed by immunoblot (10% SDS-PAGE) using specific antibodies as indicated. (E) PHA-
stimulated PBMCs were mock-infected (2) or infected with 100 ng of HIV-1 NL4-3 per 106 cells, in the absence or the presence of 0.5 mM SQ and
harvested at the indicated D.P.I. Aliquots of cell lysates containing equal amounts of proteins were analyzed by immunoblot using specific antibodies
as indicated. Results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0047272.g001
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Figure 2. HIV-1 protease directly cleaves GCN2. (A) BHK-21 cells were transfected by electroporation with in vitro transcribed capped Sindbis
virus RNAs from plasmids pT7SV-HIV-1PR (C+HIV-1Pro), pT7SV-2Apro (C+2APro), pT7SVwt (C) for the expression of HIV-1 and PV-2A proteases. After 4 h
cells were metabolically labeled with [35S]-Met-Cys. Equivalent amounts of total protein were subjected to 12% SDS-PAGE, transferred to PDVF
membranes and subjected to autoradiography (lower panel) to visualize protease expression. The membranes were then probed with specific
antisera for detection of endogenous GCN2 and eIF4GI as indicated. (B) COS-7 cells were subjected to coupled infection/DNA transfection with
recombinant vaccinia virus (vvT7), pTM1 (2) or pTM1-derived plasmid encoding HIV-1Pro and pcDNA3.1/Myc-His plasmid, empty (2) or encoding
human or mouse GCN2. At 18 h post-transfection cells were lysed and equivalent amounts of total protein were analyzed by western blot using a
specific antiserum for detection of GCN2. (C) Affinity purified mouse or human GCN2 was incubated for 3 h at 30uC in the absence or the presence of
HIV-1 or HIV-2 proteases. Incubation was stopped by addition of SDS-PAGE sample buffer and proteins were analyzed by western blot using a specific
antiserum for detection of GCN2. (D) HeLa cell-free extracts were incubated with recombinant HIV-1Pro in the absence or the presence of 2.5 mM SQ
for the indicated times. Proteins were analyzed by western blot using specific antisera for detection of GCN2, eIF4GI, PABP or actin as indicated. (E)
Purified mouse and human GCN2 GST-fusion proteins were incubated in the presence of recombinant HIV-1Pro for 3 h at 30uC. Proteins were resolved
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GCN2 fragments detected, in the in vivo and the in vitro
experiments, using an anti-GCN2 antibody directed against the
central portion of the kinase (aa 419–1024).
HIV-1 protease cleavage abrogates GCN2 activity
To test whether the proteolytic cleavage by HIV-1Pro led to the
inactivation of GCN2, we assayed GCN2 in vitro activity after
incubation with HIV-1Pro. Incubation of GCN2 with HIV-1Pro
previous to the eIF2alpha kinase assay rendered a cleaved form of
GCN2 which was just slightly phosphorylated and unable to
phosphorylate eIF2alpha (Figure 3A, lane 3). To make sure that
this effect was due to the proteolytic activity of HIV-1Pro, we also
performed the assay in the presence of saquinavir, which was
added just before the incubation of the protease with GCN2
(Figure 3A, lane 5) or, alternatively, after the incubation of the
kinase and the protease, just before initiating the kinase assay
(Figure 3A, lane 6). The presence of saquinavir prevented GCN2
cleavage by the viral protease and allowed phosphorylation of the
kinase and of eIF2alpha. Thus, we unequivocally concluded that
HIV-1Pro activity on GCN2 causes the inactivation of the kinase.
To further investigate the observed effect of HIV-1Pro action on
GCN2 activity, we expressed, purified and assayed two polypep-
tides equivalent to those obtained by HIV-1Pro action on human
GCN2, i.e., GCN2 aa 1–560 and aa 561–1649, respectively
(Figure 3B). The amino-terminal polypeptide was quite inactive
(Figure 3C, lanes 3 and 4), but the carboxi-terminal protein
fragment retained some of the ability to phosphorylate eIF2alpha
in the presence of HIV-1 RNA (Figure 3C, lanes 5 and 6),
although it was significantly lower than the activity shown by the
full length GCN2 protein (Figure 3C, lanes 7 and 8). This result
corroborates the fact that GCN2 proteolytic cleavage by HIV-1Pro
leads to the inactivation of the kinase.
GCN2 activity inhibits HIV-1 RNA translation
We wanted to test whether the activity of GCN2 had an effect
on the synthesis of HIV-1 proteins. To this end, we used two
plasmids encoding the HIV-1 genome in which luciferase or GFP
genes were inserted into the pNL4-3 nef gene (pNL4-3.Luc.R-E-
and pNL4-3.GFP.R-E-). First, we co-transfected HeLa cells with
HIV-1 constructs (pNL4-3.Luc.R-E- or pNL4-3.GFP.R-E-) or
pcDNA-Luc, along with the plasmids encoding either wild type
GCN2 or the inactive mutant GCN2-K618R. Luciferase activity
and GFP expression were significantly higher in cells over-
expressing GCN2-K618R when compared with the ones bearing
wild type GCN2 (Figure 4 A and B), suggesting a possible negative
effect of GCN2 activity on HIV-1 protein synthesis. We also
wanted to analyze whether the absence of GCN2 in cells could
affect HIV-1 protein expression. To do so, we transfected the
plasmids pNL4-3.Luc.R-E- or pcDNA-Luc in MEFs devoid of
GCN2 (Figure 4E) or in HeLa cells showing low levels of GCN2
due to the stable expression of a specific interferring RNA (RNAi
4) (Figure 4 C and D). In both cases the relative luciferase
expression from the HIV-1 clone was significantly increased (more
than 2-fold) in cells with low or absent GCN2 activity when
compared with wild type MEFs or HeLa cells bearing a unspecific
RNAi. Moreover, in HeLa cells where GCN2 was knocked down
we found high levels of GFP and HIV-1 p24 proteins compared to
cells bearing normal levels of GCN2 (Figure 4C). These results
suggest that GCN2 activity inhibits HIV-1 protein synthesis.
HIV-1 RNA activates GCN2 in cells
We performed transfection with the above mentioned HIV-1
RNA-encoding plasmids in a BHK-21 cell line that over-expresses
the regulatory subunit of PP1 phosphatase, GADD34, rendering
cells with low levels of phosphorylated eIF2alpha, BHK-A1
(Figure S1). In these cells the expression of HIV-1 constructs
induced a significant phosphorylation of GCN2 and the subse-
quent increase in the levels of phosphorylated eIF2alpha, which
was also observed in MEFs and HeLa cells (Figure 5 A, B and C)
transfected with plasmids encoding HIV-1 RNA. It is also
noteworthy that the amount of GFP, as a reporter of viral protein
synthesis, was higher in the BHK-A1 cell line and in GCN2 knock
out (GCN22/2) than in wild-type MEFs (Figure 5 A and B). We
also observed that luciferase activity expressed from a HIV-1 RNA
was higher in BHK-A1 cells, in cells expressing a non-phosphor-
ylatable form of eIF2alpha and in GCN22/2 MEFs than in the
respective control cells, BHK-C and wild type MEFs (Figure 5 D,
E and F). This increase should be caused by differences in
translation, given that the levels of the luciferase-encoding HIV-1
RNA did not rise in those cells (Figure 5 D and E). Thus we can
conclude that HIV-1 RNA activates GCN2, which in turn
phosphorylates eIF2alpha leading to the inhibition of HIV-1 RNA
translation.
Discussion
In eukaryotic cells the translation of mRNAs into proteins is
mainly regulated at the initiation step, where regulation of the
eIF2 function by phosphorylation of its alpha subunit by specific
protein kinases (eIF2alpha kinases) plays a critical role, given that
eIF2alpha phosphorylation leads to a general inhibition of protein
synthesis. Synthesis of viral proteins relies on the host cell
translation machinery and thus is similarly regulated. In fact,
phosphorylation of eIF2alpha by activated eIF2alpha kinases PKR
and GCN2 has been shown to be an important mechanism for
inhibition of viral protein synthesis and viral cycle progression
[14,26].
Here we report that the presence of HIV-1 RNA increases
GCN2 eIF2alpha kinase activity in vitro and that this increase is
dependent on the m2 motif in the HisRS-related domain of the
kinase. This effect of a viral RNA on GCN2 activity was previously
observed for the genomic RNA of Sindbis virus [14], suggesting
that GCN2 is an RNA binding protein which senses the presence
in the cells of viral RNAs through its HisRS-related domain in
order to activate an antiviral response. Unlike the previous report
on Sindbis virus [14], we have not yet identified the RNA
sequences of HIV-1 RNA responsible for the activation of GCN2.
As shown in this work, the introduction of HIV-1 RNA by
transfection of cells with an HIV-1-encoding cDNA produced the
activation of GCN2 and a subsequent increase in the levels of
phosphorylated eIF2alpha, similar to what was observed in vitro.
The consequence of this fact is a reduction in the levels of proteins
whose synthesis depends on the translation of HIV-1 RNA and,
finally, it could lead to diminished virus production. Its is not
surprising that phosphorylation of eIF2alpha led to the inhibition
of the viral protein synthesis, as has been widely proven that over-
expression and activation of the eIF2alpha kinase PKR produces
the same effect [17,27]. The novelty of our results is that the
inhibitory phenomenon is due to the activation of GCN2, given
that it has been observed by comparison of HIV-1 protein
in SDS-PAGE and stained with Coomassie blue. Shown in the lower box is the GCN2 sequence obtained by Edman degradation of the indicated C-
terminal fragments. Results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0047272.g002
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expression between wild type and GCN2 knock out cells, and in
BHK-21 cells (control and over-expressing an eIF2alpha phos-
phatase activator) in which PKR expression is extremely low
compared with other cell types [28]. Thus, the absence of GCN2
in normal cells or the maintenance of low levels of phosphorylated
eIF2alpha in cells with a very low presence of PKR favors the
expression of HIV-1 proteins.
The relevance of PKR activation and eIF2alpha phosphoryla-
tion in HIV-1 protein expression and viral cycle progression is
illustrated by a number of countermeasures employed by the virus
to prevent PKR response, including viral products and cellular
proteins [17]. Therefore, PKR is inhibited by the presence of large
amounts of viral TAR RNA and by binding of the HIV-1 Tat
protein [29], but also by direct interaction with two cellular RNA
binding proteins, the TAR RNA binding protein (TRBP) [30] and
adenosine deaminase acting on RNA 1 (ADAR1) [27,31]. These
mechanisms seem to make the innate antiviral response ineffective
and allow the virus to replicate in permissive cells. Here we show
that in cells (MT-2 and PBMC) infected with HIV-1, GCN2 is
proteolytically degraded and that its proteolytic cleavage is
prevented by the presence of the specific inhibitor of HIV-1Pro
saquinavir. Moreover, the presence of saquinavir increased
eIF2alpha phosphorylation, probably due to the activation of
uncleaved GCN2. Since GCN2 levels seem to increase with PHA
treatment and HIV-1 infection, we can speculate that activation of
cells and HIV-1 infection can promote the establishment of an
antiviral state that includes GCN2 activation and eIF2alpha
phosphorylation, being in part counteracted by the proteolytic
degradation of GCN2. Theses findings are consistent with
previous reports showing that HIV-1Pro cleaves other proteins
involved in the regulation of protein synthesis, such as the
translation initiation factors eIF4GI and PABP [20,24]; this
cleavage inhibits cellular protein synthesis, but allows translation of
viral RNA [32] which in turn also needs active eIF2alpha. In good
agreement with these observations, is the fact that during HIV-1
infection the breakage of GCN2 showed kinetics coinciding with
those observed for eIF4GI.
Our results demonstrate that HIV-1Pro cleavage of GCN2
renders an inactive eIF2alpha kinase, although, according to the
break site identified, the C-terminal portion of the protein retains
the eIF2alpha kinase and HisRs-related domains, responsible for
the activity and the activation of the protein, respectively. In fact, it
seems that this fragment has some residual activity compared to
the full-length protein. This apparent discrepancy could be
explained by the possible existence of an additional minor
cleavage site in the kinase or the HisRS-related domain. Due to
the low sequence identity between HIV-1Pro known substrates and
also to the lack of an obvious consensus cleavage motif [33,34], it is
difficult to say if GCN2 is a good substrate for the viral protease,
although the cleavage site in GCN2 meets the apparent
requirement of hydrophobic amino acids. Our results in HeLa
cell-free extracts showed that GCN2 was completely broken after
15 min of protease treatment, whereas after 30 min significant
amounts of eIF4GI and, especially, PABP remained intact,
suggesting that GCN2 is an excellent substrate for the protease
and that its specific breakage could favor HIV-1 cell cycle
progression.
All these findings taken together would point to the following
plausible scenario for the role of GCN2 in the antiviral response
against HIV-1: in the late phase of the viral life cycle, when there is
a huge production of viral mRNA to be translated into proteins for
virion assembly and maturation, viral RNAs could activate GCN2,
which subsequently would phosphorylate eIF2alpha, leading to the
inhibition of viral protein synthesis. The translation of some viral
mRNAs brings about the appearance of HIV-1Pro, which
inactivates GCN2 by proteolytic cleavage, preventing phosphor-
ylation of eIF2alpha and allowing the translation of viral proteins
and the progression of the viral cycle. It is possible that the
discovery of specific activators of GCN2 could help prevent virus
replication and the spread of infection.
Materials and Methods
Plasmids and in vitro transcription
The pTM1-HIV-1 PR plasmid containing a cDNA fragment
encoding the gene of HIV-1 protease in the pTM1 vector [35] has
been described previously [20]. The plasmids pT7SV-HIV-1PR,
pT7SV-2Apro and pT7SVwt were also described previously [25].
The cDNA containing the entire open reading frame of human
GCN2 was subcloned into the plasmid pcDNA3.1/Myc-His
(Invitrogen) by PCR amplification combined with restriction
endonuclease cuts from different cDNA partial clones. This cDNA
was used to generate the plasmids encoding the fragments of
human GCN2 corresponding to amino acids 1–560 and 561–
1649. The plasmids pGST-mGCN2 (419–1024) and pGST-
hGCN2 (525–1024) were constructed by cloning the PCR-
amplified cDNA fragments encoding the amino acids 419 to
1024 of mouse GCN2 and 525 to 1024 of human GCN2,
respectively, into the plasmid pGEX-4T (GE Healthcare). The
HIV-1 cDNA cloned into the plasmid pBH10 [36] was subcloned
into the plasmid BlueScript KS (+/2) (Stratagene) in order to
allow its transcription from a T7 promoter (pBS-HIV-1).
Plasmids pT7SV-HIV-1PR, pT7SV-2Apro, pT7SVwt and
pBS-HIV-1 were linearized and in vitro transcribed using the
T7 RNA polymerase kit (Promega) in order to produce capped
recombinant genomic Sindbis virus (SV) mRNAs and genomic-
length HIV-1 RNA.
The following reagent was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: pNL4-3.Luc.R-E- from Dr. Nathaniel Landau
[37,38]. An equivalent construct in which the firefly luciferase gene
Figure 3. HIV-1 cleavage inhibits GCN2 eIF2alpha kinase activity. (A) Affinity purified human GCN2 was incubated for 30 min at 30uC in the
absence or the presence of HIV-1Pro and in the absence or the presence of 2.5 mM SQ, as indicated, prior to being assayed in an eIF2alpha kinase assay
(lanes 1–5). In lane 6, SQ was added after incubation of GCN2 with the protease, just before initiating the eIF2alpha kinase assay. HIV-1 RNA was only
present during the kinase assay. Incubation was stopped by addition of SDS-PAGE sample buffer and proteins were analyzed by western blot using
specific antisera to detect eIF2alpha phosphorylated on serine 51, total eIF2alpha, and phosphorylated and total GCN2. Similar results were obtained
from a duplicate experiment. (B) Schematic representation of the structural domains of human GCN2 and the generated GCN2 fragments according
to the HIV-1Pro cleavage site. The 1649 amino acid GCN2 sequence is illustrated by a larger box and the figure is drawn to scale. Highlighted domains
include the N-terminal (black); the ‘Pseudokinase’ (dark grey) that is related to sub-domains I–XI of eukaryotic protein kinases; the conserved two
lobes of the eIF2alpha kinase domain (black), separated by a large insert (light grey); the HisRS-like domain (dark grey); and a C-terminal domain (light
grey). The numbers refer to the amino acid residues. (C) In vitro eIF2alpha kinase assay of purified full-length human GCN2 (1–1649) and the
generated GCN2 fragments according to the HIV-1Pro cleavage site (1–560 and 561–1649) in the absence or the presence of HIV-1 RNA as indicated.
Proteins were analyzed by western blot using specific antisera to detect eIF2alpha phosphorylated on serine 51, total eIF2alpha, and full-length GCN2
or fragments (anti-myc). Similar results were obtained from a duplicate experiment.
doi:10.1371/journal.pone.0047272.g003
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Figure 4. Absence of GCN2 favor HIV-1 protein expression. (A, B) HeLa cells were co-transfected with plasmids encoding wild type GCN2 or
the inactive mutant GCN2-K618R and also with a mixture of HIV-1 encoding plasmids pNL4-3.Luc.R-E- and pNL4-3.GFP.R-E-. Cells were harvested 24 h
after transfection. Aliquots of cell lysates containing equal amounts of proteins were analyzed by western blot using specific antisera to detect GCN2,
eIF2alpha and GFP (A). Luciferase activity was measured, and results are shown as the ratio between the activity in cells over-expressing GCN2-K618R
mutant and in cells over-expressing wild type GCN2. * P,0.05 vs. WT (B). (C, D) Normal HeLa cells (no siRNA) and HeLa cells stably expressing a
control siRNA (siRNA 3) or a specific siRNA for GCN2 knock down (siRNA 4) were transiently transfected with a mixture of HIV-1 encoding plasmids,
pNL4-3.Luc.R-E- and pNL4-3.GFP.R-E-. Cells were harvested 24 h after transfection. Aliquots of cell lysates containing equal amounts of proteins were
analyzed by western blot using specific antisera to detect GCN2, eIF2alpha, GFP and HIV-1-p24 (C). Luciferase activity was also measured, and results
are shown as the ratio between the activity in cells expressing siRNA 3 or siRNA 4 and in normal cells (no siRNA). * P,0.01 vs. no RNAi and RNAi 3 (D).
HIV-1 Counteracts GCN2 Inhibitory Effect
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e47272
was replaced by the green fluorescent protein (GFP) gene (pNL4-
3.GFP.R-E-), was kindly supplied by Dr. Gustavo del Real (Centro
Nacional de Biotecnologı´a, Madrid, Spain).
Cell culture, virus infection and transfection
MEF wild type, GCN2 knock out [39] or with a homozygous
knock-in mutation for eIF2alpha (S51A) [40], HeLa, COS-7,
BHK-21 and HEK 293T cell lines were grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% (v/v) foetal
bovine serum (FBS), 2 mM glutamine, antibiotics and non-
essential amino acids. MT-2 cells (human T-cell leukemia virus
type 1 (HTLV-1)-infected cell line) were maintained in complete
RPMI 1640 growth medium (Biochrom AG) supplemented with
5% FBS, 2 mM glutamine, 1% ampicillin, 1% cloxacillin, 0.32%
gentamicin. Human Peripheral Blood Mononuclear Cells (PBMC)
(E) Wild type (WT) and GCN2 knock out (GCN22/2) MEF were transiently transfected by electroporation with a pcDNA-based plasmid encoding
luciferase protein (pcDNA-Luc), as a control, or with an HIV-1 encoding plasmid, pNL4-3.Luc.R-E-. Cells were harvested 24 h after transfection and
luciferase activity was measured in cell extracts. Luciferase activity produced in cells from the HIV-1-encoding plasmid was normalized dividing it by
the activity produced in cells from pcDNA-Luc plasmid. Results represent the ratio of normalized luciferase activity between wild type MEFs (set as
one) and GCN22/2. * P,0.005 vs. WT. Results represent the mean of three to four independent experiments and error bars indicate the standard error
(SE).
doi:10.1371/journal.pone.0047272.g004
Figure 5. GCN2 is activated in cells expressing HIV-1 RNA. (A) BHK-C and BHK-A1 cells were transfected with a pcDNA-based plasmid
encoding luciferase protein (pcDNA-Luc) or with a mixture of HIV-1 encoding plasmids, pNL4-3.Luc.R-E- and pNL4-3.GFP.R-E-. Aliquots of cell lysates
containing equal amounts of proteins were analyzed by western blot using specific antisera to detect eIF2alpha phosphorylated on serine 51,
phosphorylated or total GCN2, GFP and actin. (B) The same as in (A), but using wild type (WT) and GCN2 knock out (GCN2-/-) MEFs. The membrane
was probed with different antisera to detect eIF2alpha phosphorylated on serine 51, total eIF2alpha, phosphorylated or total GCN2 and GFP. (C) The
same as in (A) and (B), but using HeLa cells. In this case the transfection was done by electroporation. The membrane was probed with different
antisera to detect eIF2alpha phosphorylated on serine 51, total eIF2alpha, phosphorylated or total GCN2, GFP and actin. Similar results were obtained
from duplicate experiments. (D and E) In samples equivalent to those of the experiments described in (A) and (B) where cells were transfected with
pNL4-3.Luc.R-E- plasmid, luciferase activity was measured and HIV-1 RNA quantified. Relative values of both are shown as the ratio between GCN2-/-
MEFs or BHK-A1 and the corresponding control cells (wild type MEFs or BHK-C), whose value was set as one. Data are expressed as mean 6 SE. * P ,
0.05 vs. BHK-C (D) or WT (E). (F) Wild type (WT) and S51A MEFs were transiently transfected by electroporation with a pcDNA-based plasmid encoding
luciferase protein (pcDNA-Luc), as a control, or with an HIV-1 encoding plasmid, pNL4-3.Luc.R-E-. Cells were harvested 24 hr after electroporation and
luciferase activity was measured in cell extracts. Luciferase activity produced in cells from the HIV-1-encoding plasmid was normalized dividing it by
the activity produced in cells from pcDNA-Luc plasmid. Results represent the ratio of normalized luciferase activity between wild type MEFs (set as
one) and S51A MEFs. * P , 0.01 vs. WT.
doi:10.1371/journal.pone.0047272.g005
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were derived from healthy voluntary donors, and obtained from
leukophoresed blood by FicollTM gradient (Pharmacia Fine
Chemicals, Uppsala, Sweden) and elutriated by centrifugation.
After washing with phosphate buffered saline (PBS), cells were
seeded in RPMI 1640 medium (Biochrom AG) with 10% FBS, 1%
L-glutamine, antibiotics, and 50 IU/ml IL-2. PBMC were
stimulated for 48 h with phytohemaglutinine (2 mg/ml) and
interleukin 2 (IL-2) (100 IU/ml). All cell lines were cultured at
37uC in a 5% CO2 atmosphere. PBMC were kindly provided by
the Spanish HIV BioBank integrated in the Spanish AIDS
Research Network (RIS) 1 [41].
PBMC and MT-2 cells were infected or mock-infected with 10
or 100 ng of p24gag per 106 cells of HIV-1NL4–3 for 2 h (100 ng of
p24gag per 106 cells has been evaluated to be equivalent to 1–2
viral particles per cell) [42], washed three times and incubated in
fresh medium. At 1 to 5 days post-infection (dpi), cells were
harvested and washed 3 times with PBS, and the dry pellet was
stored at 280uC before lysis.
BHK-21 cells were electroporated with 30 mg of recombinant
SV genomic RNA in a final volume of 50 ml as described in [25].
Electroporated cells were maintained in growth medium, and, at 4
h post-electroporation, metabolically labelled with [35S]Met/Cys
mixture (Promix, Amersham), as described previously [14] and
lysed in sample buffer. Coupled infection/DNA transfection of
COS-7 cells with recombinant vaccinia virus (vvT7), pTM1-
derived plasmids and plasmids encoding human and mouse
GCN2, have previously been described in detail [43].
For transient transfections, HEK 293T and HeLa cells were
plated on 60-mm dishes and transfected with plasmids (6–12 mg/
dish) using LipofectamineTM and PlusTM Reagents (Invitrogen)
according to the manufacturer’s instructions. Similarly, BHK-21
and MEF cells were transfected using the cationic polymer reagent
jetPEITM (PolyPlus-transfection) according to the manufacturer’s
instructions.
Virus production and titration
Virus stocks were prepared by amplification of HIV-1NL4-3 in
MT-2 cell line (ATCC) or PHA+IL-2 activated PBMC. Physical
titers of viral stocks were evaluated by quantification of HIV p24gag
by ELISA kit (Innotest HIV-1 antigen mAb; Innogenetics) [44].
Lentivirus and stable transduction of shRNAs
The following targeted shRNAs in lentiviral construct plasmid
pLKO.1-Puro [45] were purchased from Sigma-Aldrich: GCN2
(XM_496066) Clone 1 TRCN0000078648, Clone 2
TRCN0000078649, Clone 3 TRCN0000078650, Clone 4
TRCN0000078651, Clone 5 TRCN0000078652. Lentiviruses
were produced by co-transfection of HEK293T Phoenix cells with
pLKO.1-Puro shRNA-encoding plasmids, pMD2G (Addgene)
and pSPAX2 (Addgene), using jetPEITM (PolyPlus-transfection).
Viruses were harvested at 24 and 48 h post-transfection and
infections of HeLa cells were carried out in the presence of 8 mg/
ml of polybrene (Sigma-Aldrich). Following transduction, cells
were selected with 1 mg/ml puromycin (Sigma-Aldrich).
Protein purification
For purification of GST fusion proteins, Escherichia coli BL21
cells were transformed with plasmids pGST-mGCN2 (419–1024)
and pGST-hGCN2 (525–1024), lysed by sonication, and the
fusion proteins were then purified as previously described [46]
using glutathione-sepharose (GE Healthcare). Purification of Myc-
and 6xHis-tagged GCN2 full-length, GCN2-K618R, GCN2-m2
and GCN2 fragments was done as previously described [14]. HIV-
1Pro was provided by I. Pichova through the Centralised Facility
for AIDS Reagents. Purified HIV-2 protease (HIV-2Pro) [47] was
obtained through the NIH (National Institutes of Health) AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID (National Institute of Allergy and Infectious Diseases),
NIH, Bethesda, MD, U.S.A., from Dr Bret Shirley and Mr
Michael Cappola (Boehringer Ingelheim Pharmaceuticals).
Protease cleavage assays
Crude HeLa S10 extracts were incubated with 2.5 ng/ml of
recombinant HIV-1Pro and reactions were stopped by adding
sample buffer. In other experiments, purified preparations of
mouse or human Myc- and 6xHis-tagged GCN2 were incubated
with 2.5 ng/ml of recombinant HIV-1Pro, or HIV-2Pro in cleavage
buffer (50 mM sodium phosphate, pH 6.0, 25 mM NaCl, 5 mM
EDTA and 1 mM DTT) for 3 h at 30uC. In order to map the
cleavage sites of HIV-1Pro on GCN2, 50 mg of recombinant GST–
tagged mouse or human GCN2 protein were incubated with 1 mg
of recombinant HIV-1Pro in a total volume of 50 ml for 3 h at 30uC
in cleavage buffer. Cleavage products were separated by SDS-
PAGE, transferred to a PVDF membrane (ImmobilonH–P,
Millipore) and then subjected to automated Edman degradation
with an Applied Biosystems Procise Sequencer in the Proteomics
Service of Centro de Investigaciones Biolo´gicas (CSIC).
In vitro kinase activity
Affinity purified GCN2 wild type and mutants (m2 and K618R)
were assayed for their ability to phosphorylate eIF2alpha in the
presence or the absence of HIV-1 RNA, as previously described
[14]. In some experiments 32P-c-ATP was included in the kinase
reaction mix and phosphorylated eIF2alpha was detected by
autoradiography of the corresponding SDS-PAGE dried gel. In
other kinase assays only non-radiactive ATP was used and
phosphorylated eIF2alpha and GCN2 were detected by western
blot using phosphospecific antibodies.
Western blotting
Proteins subjected to SDS-PAGE were transferred to a PVDF
membrane (ImmobilonH–P, Millipore) for western blot analysis.
Western blots were performed using the following antibodies:
mouse anti-myc (Sigma); rabbit anti-eIF2alpha phospho-Ser51
(Cell Signaling); rabbit anti-eIF2alpha (Santa Cruz); rabbit anti-
GCN2 phospho-Thr898 (Cell Signaling, Abcam); rabbit anti-
GCN2 [8]; eIF4GI anti-serum raised against peptides derived
from the C-terminal region of the human eIF4GI [43]; rabbit anti-
sera raised against the C- and N-terminal region of human PABP
[48]; and mouse ascites of a monoclonal antibody against HIV-1
p24 antigen (Centralised Facility for AIDS Reagents, NIBSC,
Potters Bar, Herts., U.K.). Goat anti-(rabbit IgG) and goat anti-
(mouse IgG) antibodies coupled to peroxidase (Promega) were also
used. Immunoreactive bands were visualized by using ECLTM and
ECL Plus Western Blotting Detention Systems (GE Healthcare)
and autoradiography (Agfa Curix RP2 Plus).
Luciferase activity determination
After different times post-transfection, cells were washed twice
with PBS and lysed using Passive Lysis Buffer (Promega). After
removal of cell debris, equal amounts of total protein were used to
measure luciferase activity (Luciferase Assay System, Promega) in
the lysates.
RNA extraction, reverse transcription and real-time PCR
Total RNA was extracted using the SV Total RNA Isolation
System (Promega), following the manufacturer’s instructions. For
HIV-1 Counteracts GCN2 Inhibitory Effect
PLOS ONE | www.plosone.org 10 October 2012 | Volume 7 | Issue 10 | e47272
determination of luciferase mRNA expression, 1 mg of total RNA
was reverse-transcribed in a 20 ml reaction mixture by using a
Reverse Transcription System (Promega) and random primers
following the manufacturer’s instructions. The LightCyclerH
FastStart DNA MasterPLUS SYBR Green I system (Roche) was
used for real-time PCR amplification/quantification using 2 ml of
first strand cDNA reaction as a template. The level of GAPDH
mRNA in each sample was determined in order to normalize for
differences in total RNA amounts. The data were derived from at
least three independent reverse-transcription reactions and real-
time PCR performed in duplicate. Data analysis to determine
relative luciferase mRNA expression was performed according to
the 2-DDCT method [49]. Primers were designed to amplify
fragments in the open reading frame of luciferase (nucleotides
1343-1540) and GAPDH (nucleotides 493–775).
Statistical Analysis
All data are reported as means 6 SE of the results obtained
from at least three independent experiments. Data were analyzed
by two-tailed, unpaired Student’s t test. Differences were
considered significant when P,0.05.
Supporting Information
Figure S1 GCN2 and PKR expression and eIF2alpha
kinase response in BHK-C and BHK-A1 cells. (A) BHK-C
and BHK-A1 cells were maintained for 1 h in normal growth
medium containing or not thapsigargin (Tg) or in growth medium
without methionine (-Met). Aliquots of cell lysates containing equal
amounts of proteins were resolved into 10% SDS-PAGE and
transferred to a PVDF membrane. The membrane was probed
with different antisera to detect eIF2alpha phosphorylated on
serine 51, phosphorylated or total GCN2 and actin. (B) BHK-C
and BHK-A1 cells or wild type (WT), GCN2 knock out (GCN2-/-)
and PKR knock out (PKR-/-) MEFs were maintained in normal
growth medium before lysis. Aliquots of cell extracts containing
equal amount of proteins were resolved into 10% SDS-PAGE and
transferred to a PVDF membrane. The membrane was probed
with different antisera to detect GCN2, PKR and actin. Results
are representative of at least three independent experiments.
(TIF)
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